|drug83||Ascorbic Acid Wiki||0.50|
|drug522||Hydroxychloroquine Sulfate Wiki||0.30|
|D055370||Lung Injury NIH||0.25|
|D011024||Pneumonia, Viral NIH||0.14|
|D055371||Acute Lung Injury NIH||0.13|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.13|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.11|
There is one clinical trial.
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
Description: Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or coughMeasure: Lower respiratory tract infection (LRTI) rates Time: 28 days from enrolment
Description: Cumulative incidence of hospitalization or mortalityMeasure: Incidence of hospitalization or mortality Time: Day 28 after enrolment
Description: Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabsMeasure: Change in upper respiratory viral shedding Time: Day 1 through Day 14 after enrolment
Description: Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuationMeasure: Rate of participant-reported adverse events Time: 28 days from enrolment